Lenvatinib Mesylate Intermediate CAS 15568-85-1 Purity>97.0% (HPLC) Factory

5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) ndi yapakatikati ya Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib ndi mankhwala a khansa ya chithokomiro opangidwa ndi Eisai Corporation yaku Japan (Code: E7080), ya inhibitor ya oral multi-receptor tyrosine kinase (RTK) ndipo imatha kuletsa ntchito ya kinase ya vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), ndi VEGFR3 (FLT4).Lenvatinib ingalepheretsenso kukhudzidwa kwa ma RTK ena mu pathological angiogenesis, kukula kwa chotupa, ndi kukula kwa khansa kupatulapo ntchito zawo zachibadwa zama cell kuphatikizapo fibroblast growth factor (FGF) zolandilira FGFR1, 2, 3, ndi 4;Kukula kwa ma platelet-derived growth factor receptor (PDGFR [alpha]), KIT, ndi RET.[Zizindikiro]: Lenvatinib ndi oyenera kuchiza odwala a chithokomiro khansa ya m'deralo zisadzachitikenso kapena metastasis mtundu, progressivity mtundu ndi radioactive ayodini-refractory differentiated mtundu.Pa February 13, 2015, US FDA idavomereza Lenvatinib mankhwala ochizira khansa ya chithokomiro.Lenvatinib ndi multi-target enzyme inhibitor, yomwe imatha kuletsa VEGFR2 ndi VEGFR3 (vascular endothelial growth factor receptor).Dzina la malonda la Lenvatinib ndi Lenvima.Pa Meyi 20, 2015, European Medicines Agency (EMA) idavomereza Lenvatinib kuti azitha kuchiza khansa ya chithokomiro, yapapillary, follicular, mtundu wa Hurthle (DTC).M'mayeserowo, nthawi yapakati yopulumuka kwa odwala omwe adalandira chithandizo cha radioactive ayodini-refractory DTC omwe adalandira chithandizo ndi Lenvatinib anali miyezi 18 pomwe mtengo wa odwala omwe atenga placebo ndi miyezi itatu yokha.